NSE SYNGENE · BSE 539268 · Biotechnology & Drugs · NIFTY 500

Syngene International Share Price

Market closed · updated 25 Sep, 4:50 PM IST

₹380.00 ▼ −₹1.30 · 0.34% NSE · as of 24 Sep 2026, 9:57 AM · BSE ₹380.30

Today's range

₹379.00Low₹384.20High

52-week range

₹360.35Low · 21 Sep 2026₹678.00High · 7 Jan 2026

Syngene International Overview

Where the price stands, how it has moved and how it sits against its averages.

Syngene International shares last traded at ₹380.00 on the NSE, down 0.34% on the day. That is 44.0% below the 52-week high of ₹678.00 and 5.5% above the 52-week low of ₹360.35. The stock trades at 79.96× earnings, above the sector average of 46.34. Its market value is ₹15,385 Cr.

Price returns

1 Day▼ −0.34%

5 Days▲ +0.46%

This month▼ −4.72%

3 Months▼ −13.79%

6 Months▼ −8.81%

This year▼ −41.34%

1 Year▼ −40.67%

Against the market: 1 Month ▼ −3.84% · 3 Months ▼ −11.30% · 6 Months ▼ −8.27% · This year ▼ −33.20% · 1 Year ▼ −34.91%

Shading grows with the size of the move. Prices refresh every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next update from Mon 28 Sep, 9:15 AM.

Moving averages — price is above 1 of 6

300-day average₹467.87 ▼ price 18.8% below
100-day average₹424.66 ▼ price 10.5% below
50-day average₹400.59 ▼ price 5.1% below
20-day average₹391.69 ▼ price 3.0% below
10-day average₹381.19 ▼ price 0.3% below
Today's price₹380.00
5-day average₹378.40 ▲ price 0.4% above

Averages above today's price sit higher on the ladder. Price above most of its averages is usually read as an upward trend.

Syngene International Financial Results

Revenue and net profit in ₹ crore, with the full statements underneath.

Revenue₹ crore

3,739

Net profit₹ crore · losses below zero

510

317

Year by year

Fiscal year	Revenue	Growth	Net profit	Net margin	EPS	Dividend
FY 2026	₹3,739 Cr	▲ +2.6%	₹317 Cr	8.5%	₹7.87	₹1.25
FY 2025	₹3,642 Cr	▲ +4.4%	₹496 Cr	13.6%	₹12.33	₹1.25
FY 2024	₹3,489 Cr	▲ +9.3%	₹510 Cr	14.6%	₹12.69	₹1.25
FY 2023	₹3,193 Cr	▲ +22.6%	₹464 Cr	14.5%	₹11.51	₹0.50
FY 2022	₹2,604 Cr	▲ +19.2%	₹396 Cr	15.2%	₹9.82	₹0.50
FY 2021	₹2,184 Cr	▲ +8.6%	₹405 Cr	18.5%	₹10.11	—
FY 2020	₹2,012 Cr	—	₹412 Cr	20.5%	₹10.35	₹0.00

Revenue₹ crore

1,037

736

Net profit₹ crore · losses below zero

183

−9

Quarter by quarter

Quarter	Revenue	vs prev. qtr	Net profit	Net margin	EPS
Q1 FY27	₹736 Cr	▼ −29.0%	−₹9 Cr	−1.2%	−₹0.22
Q4 FY26	₹1,037 Cr	▲ +13.0%	₹148 Cr	14.3%	₹3.67
Q3 FY26	₹917 Cr	▲ +0.7%	₹15 Cr	1.6%	₹0.37
Q2 FY26	₹911 Cr	▲ +4.1%	₹67 Cr	7.4%	₹1.67
Q1 FY26	₹875 Cr	▼ −14.1%	₹87 Cr	9.9%	₹2.15
Q4 FY25	₹1,018 Cr	▲ +7.9%	₹183 Cr	18.0%	₹4.53
Q3 FY25	₹944 Cr	▲ +5.9%	₹131 Cr	13.9%	₹3.26
Q2 FY25	₹891 Cr	—	₹106 Cr	11.9%	₹2.64

Balance sheet — FY26

Owes (liabilities)Shareholders' equity

31%

69%

Total assets₹7,055 Cr
Total liabilities₹2,216 Cr
Shareholders' equity₹4,839 Cr
Total debt₹458 Cr
Cash & investments₹1,289 Cr
Current ratio1.38×
Revenue growth, 5 yr11.35% a year
EPS growth, 5 yr−4.89% a year
Operating margin (TTM)10.14%
Net margin (TTM)6.14%

Cash flow — FY26

Operating activities

▲ ₹915 Cr

Investing activities

▼ −₹860 Cr

Financing activities

▼ −₹215 Cr

Free cash flow

▲ ₹547 Cr

Net change in cash

▼ −₹139 Cr

Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.

Full financial statements, FY20–FY26

₹ crore	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Total revenue	2,011.90	2,184.30	2,604.20	3,192.90	3,488.60	3,642.40	3,738.70
Cost of revenue	565.20	583.90	813.80	929.40	999.90	1,011.50	991.80
Gross profit	1,446.70	1,600.40	1,790.40	2,263.50	2,488.70	2,630.90	2,746.90
Operating expenses	1,627.70	1,769.10	2,203.30	2,575.70	2,852.90	2,996.40	3,286.00
Operating income	384.20	415.20	400.90	617.20	635.70	646.00	452.70
Depreciation	215.30	270.30	305.20	359.70	418.80	425.80	446.30
Profit before tax	516.90	469.20	484.40	593.60	620.80	659.90	410.90
Tax	104.80	64.30	88.60	129.20	110.80	163.70	94.20
Net profit	412.10	404.90	395.80	464.40	510.00	496.20	316.70
EPS (₹)	10.35	10.11	9.82	11.51	12.69	12.33	7.87
Dividend per share (₹)	0.00	—	0.50	0.50	1.25	1.25	1.25

₹ crore	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Total assets	4,162.90	4,883.20	5,563.80	5,831.00	6,151.60	6,795.90	7,054.70
Current assets	1,612.60	1,806.70	2,205.90	2,425.30	1,959.00	2,287.30	2,142.80
Cash & short-term investments	1,019.90	1,065.90	1,281.70	1,356.10	1,076.70	1,397.50	1,289.10
Inventory	25.20	59.60	179.40	332.80	238.50	155.50	141.30
Property, plant & equipment	2,197.10	2,381.50	2,688.10	2,777.20	3,617.50	4,003.20	3,970.30
Total liabilities	1,987.10	2,061.80	2,266.20	2,213.00	1,893.80	2,069.10	2,215.60
Current liabilities	1,539.20	1,133.00	1,228.90	1,188.20	1,144.20	1,396.40	1,552.30
Total debt	772.90	892.90	1,021.60	815.20	555.20	577.90	458.40
Total equity	2,175.80	2,821.40	3,297.60	3,618.00	4,257.80	4,726.80	4,839.10

₹ crore	FY20	FY21	FY22	FY23	FY24	FY25	FY26
From operations	677.10	701.20	580.60	823.50	1,042.10	1,167.60	915.20
From investing	−428.40	−628.10	−611.50	−656.40	−495.60	−744.70	−860.40
From financing	−225.50	58.00	−31.30	−342.50	−551.50	−141.70	−215.00
Capital expenditure	−643.10	−446.50	−475.50	−518.30	−510.80	−770.10	−368.20
Dividends paid	−24.10	0.00	—	−40.10	−50.30	−50.30	−50.40
Net change in cash	27.80	130.30	−61.50	−172.30	−3.90	281.50	−138.50

What Analysts Say

8 analysts

Recommendations from 8 analysts who cover Syngene International.

Buy average rating 2.38 on a 1–5 scale

Strong buyBuyHoldSellStrong sell

▲ 5 bullish (62.5%) · 2 hold (25.0%) · ▼ 1 bearish (12.5%)

Votes

Strong Buy

2 (25%)

Buy

3 (38%)

Hold

2 (25%)

Sell

0 (0%)

Strong Sell

1 (13%)

How the votes changed

Rating	3M ago	2M ago	1M ago	1W ago	Now	3-month change
Strong Buy	2	2	2	2	2	—
Buy	3	3	3	3	3	—
Hold	2	2	2	2	2	—
Sell	0	0	0	0	0	—
Strong Sell	1	1	1	1	1	—

Analyst ratings are opinions, not a guarantee of returns.

Syngene International vs Peers

Side by side with other biotechnology & drugs companies. The small bars compare each column.

Company	Price	Change	Market cap	P/E	P/B	ROE (5 yr)	Net margin	Div. yield	Rating
Syngene International	₹380.00	▼ −0.34%	₹15,385 Cr	79.96	3.17	11.06%	6.14%	0.33%	This stock
Sun Pharmaceutical Industries	₹1,853.00	▼ −0.64%	₹4,44,586 Cr	38.40	5.55	14.22%	19.12%	0.83%	Moderately Bearish
Divi's Laboratories	₹9,613.00	▲ +0.17%	₹2,55,195 Cr	73.32	11.48	16.87%	24.32%	0.41%	Bullish
Torrent Pharmaceuticals	₹4,935.00	▼ −0.90%	₹1,87,705 Cr	72.73	19.22	23.00%	15.29%	0.80%	Bullish
Cipla	₹1,404.00	▲ +1.74%	₹1,13,423 Cr	27.57	3.33	14.47%	13.74%	0.92%	Neutral
Zydus Lifesciences	₹1,180.00	▲ +0.90%	₹1,17,705 Cr	21.19	4.24	17.90%	18.51%	0.09%	Bullish

Rating = the data provider's overall technical view of each peer. Company names link to their own pages.

Shareholding Pattern

Who owns Syngene International shares, quarter by quarter (latest on top).

PromoterFIIMFOther

Jun '26

52.6%

11.8%

25.8%

9.8%

Mar '26

Dec '25

Sep '25

Holder	Sep '25	Dec '25	Mar '26	Jun '26	Change
Promoter	52.68%	52.68%	52.68%	52.59%	▼ −0.09 pts
FII	16.31%	14.96%	13.91%	11.82%	▼ −2.09 pts
MF	21.22%	22.71%	24.18%	25.78%	▲ +1.60 pts
Other	9.79%	9.65%	9.23%	9.81%	▲ +0.58 pts

Syngene International Key Metrics

Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.

Syngene InternationalBenchmarkComfortable → stretched

Valuation Is the price reasonable?

P/E (TTM)Price ÷ yearly earnings per share

79.96

▲ 73% above the sector average of 46.34

P/E, 12-month rangeLow 49.59 · high 80.01

100%

Today's P/E sits 100% of the way from its low to its high

P/BPrice ÷ book value per share

3.17

P/SPrice ÷ sales per share

4.26

P/CFPrice ÷ cash flow per share

22.74

Profitability Of every ₹100 of sales, how much is kept?

Gross marginKept after the cost of goods

75.71%

▲ above its 5-yr average of 71.52%

Operating marginKept after running costs

10.14%

▼ below its 5-yr average of 16.51%

Pre-tax marginKept before tax

8.07%

▼ below its 5-yr average of 16.62%

Net marginKept as profit

6.14%

▼ below its 5-yr average of 13.10%

Returns & efficiency How well does it use its money?

Return on equityProfit on shareholders' money

6.62%

▼ below its 5-yr average of 11.06%

Return on assetsProfit on everything it owns

4.57%

▼ below its 5-yr average of 7.20%

Return on investmentProfit on long-term capital

5.81%

▼ below its 5-yr average of 9.09%

Growth Is the business getting bigger?

Revenue — last 12 months

−3.4%

▼ shrinking

Revenue — 3 yr, a year

+5.4%

▲ growing

Revenue — 5 yr, a year

+11.4%

▲ growing

EPS — last 12 months

−56.4%

▼ shrinking (off the scale)

EPS — 3 yr, a year

−11.9%

▼ shrinking

EPS — 5 yr, a year

−4.9%

▼ shrinking

Dividend — 3 yr, a year

+35.7%

▲ growing (off the scale)

Book value — 5 yr, a year

+11.3%

▲ growing

Financial strength Can it pay its bills and debts?

Debt to equityBorrowings for every ₹1 of shareholders' money

0.09×

✓ Low debt

Current ratioShort-term assets for every ₹1 due within a year

1.38×

• Adequate

Quick ratioLike the current ratio, without inventory

1.29×

✓ Comfortable

Interest coverOperating profit ÷ interest to pay

11.48×

✓ Strong

Payout ratioShare of profit paid as dividend

15.88%

• Keeps most

Per share What each share stands for

EPS (TTM)

₹5.49

Book value

₹120.44

Cash flow

₹16.68

Dividend

₹1.25

Revenue

₹88.95

The share price is 3.16× the book value behind each share.

Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.

All 111 metrics from the data provider

Valuation

P/E excluding extraordinary items, most recent fiscal year48.55

Current Dividend Yield - Common Stock Primary Issue, LTM0.33

Price to Book - most recent fiscal year3.17

P/E Basic excluding extraordinary items - TTM79.96

P/E including extraordinary items - TTM69.51

P/E excluding extraordinary items low, trailing 12 months49.59

Price to Tangible Book - most fiscal year3.20

Dividend Yield - 5 Year Average0.16

Price to sales - most recent fiscal year4.10

Dividend Yield - indicated annual dividend divided by closing price0.33

Price to Cash Flow per share - trailing 12 month22.74

Price to Free Cash Flow per Share - most recent fiscal year30.90

P/E Normalized, most recent fiscal year40.69

P/E excluding extraordinary items high, trailing 12 months80.01

P/E excluding extraordinary items, most recent fiscal year quarter69.51

Price to sales - trailing 12 month4.26

Net Debt, LFY−8,307.00

Per share

Dividend Per Share - 5 year average0.95

Cash Flow per share - trailing 12 month16.68

Cash Flow per share - most recent fiscal year18.95

EPS including extraordinary items - trailing 12 month5.49

EPS including extraordinary items - most recent fiscal year7.87

EBITD per share - trailing 12 month22.46

Revenue/share - trailing 12 month88.95

EPS excluding extraordinary items - trailing 12 month5.49

EPS Basic excluding extraordinary items - most recent fiscal year7.87

EPS Basic excluding extraordinary items - trailing 12 month5.50

Book value per share - most recent fiscal year120.44

Dividend per share - most recent fiscal year1.25

Revenue/share - most recent fiscal year92.85

EPS Normalized - most recent fiscal year9.39

Book value (tangible) per share - most recent fiscal year119.35

Dividends per share - trailing 12 month1.25

EPS excluding extraordinary items - most recent fiscal year7.87

Cash per share - most recent fiscal year32.09

Margins

Operating margin - trailing 12 month10.14

Gross Margin - 5 year average71.52

Operating margin - 1st historical fiscal year12.11

Operating Margin - 5 year average16.51

Net Profit Margin % - 1st historical fiscal year8.47

Gross Margin - 1st historical fiscal year73.47

Net Profit Margin % - trailing 12 month6.14

Net Profit Margin - 5 year average13.10

Pretax Margin - 5 year average16.62

Pretax margin - 1st historical fiscal year10.99

Pretax margin - trailing 12 month8.07

Free Operating Cash Flow/Revenue, 5 Year Average10.17

Gross Margin - trailing 12 month75.71

Growth

EPS Change %, TTM over TTM−56.35

Revenue growth rate, 5 year11.35

EPS growth rate, 5 year−4.89

Revenue Change % - most recent quarter 1 year ago−15.84

Growth rate% - dividend, 3 year35.72

Growth rate% - EPS, 3 year−11.91

Revenue/share (5 yr growth)11.24

Free Operating Cash Flow, 5 Year CAGR14.29

Tangible Book Value, Total Equity, 5 Year CAGR11.34

Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR6.22

Capital Spending growth rate, 5 year−3.78

Revenue Change %, TTM over TTM−3.41

Growth rate% - Revenue, 3 year5.40

Book value per share growth rate, 5 year11.30

EPS Change % - most recent quarter 1 year ago−110.23

Net Profit Margin growth rate, 5 year−14.50

Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR8.45

Total Debt, 5 Year CAGR−12.48

Financial strength

Net Interest coverage - most recent fiscal year11.48

Free Cash Flow - most recent fiscal year4,966.00

LT debt/equity - most recent fiscal year0.08

Quick ratio - most recent fiscal year1.29

Payout ratio - trailing 12 month22.76

Current ratio - most recent fiscal year1.38

Current EV/Free Cash Flow, LFY42.16

Total debt/total equity - most recent fiscal year0.09

Net Interest coverage - trailing 12 month2.98

Payout ratio - most recent fiscal year15.88

Returns & efficiency

Return on average equity - 5 year average11.06

Net Income/employee - trailing 12 month3,30,245.10

Revenue/employee - most recent fiscal year56,53,989.00

Return on investment - most recent fiscal year5.81

Return on average assets - most recent fiscal year4.57

Receivables turnover - most recent fiscal year6.98

Inventory turnover - most recent fiscal year6.68

Revenue/employee - trailing 12 month53,79,857.00

Return on average assets - 5 year average7.20

Net Income/employee - most recent fiscal year4,78,941.40

Asset turnover - most recent fiscal year0.54

Return on average equity - most recent fiscal year6.62

Return on investment - 5 year average9.09

Price & volume

Market Cap15,504.82

52 week Low Date21 Sep 2026

Price - 1 Day % Change1.15

Relative (S&P500) price percent change - 13 week−11.30

Avg trading volume last 10 days0.86

Price - 13 week price percent change−13.79

Price - 52 week price percent change−40.67

Avg Trading Volume Last 3 months22.80

Price - 5 Day % Change0.46

Price % Change Month To Date−4.72

Relative (S&P500) price percent change - 04 week−3.84

52 week High Date7 Jan 2026

Price - 26 week price percent change−8.81

PDATE23 Sep 2026

Price - YTD price percent change−41.34

Relative (S&P500) price percent change - 52 week−34.91

NPRICE381.85

Relative (S&P500) price percent change - 26 week−8.27

52 week Low360.40

52 week High678.95

Beta1.12

Relative (S&P500) price percent change - Year to Date−33.20

Dividends & Corporate Events

Payouts to shareholders, splits and bonus issues, and company meetings — newest first.

Dividend per share₹ per share, by fiscal year

₹1.25

Dividend yield0.33%
Payout ratio15.88%
5-year average dividend₹0.95 a share
Latest dividend₹1.25 per share · 25 Jun 2026

Corporate calendar

29 Jul 2026MeetingAnnual General Meeting
29 Jul 2026BoardQuarterly Results
25 Jun 2026Dividend₹1.25 per share · 13% · Final dividend
23 Jun 2026MeetingPostal Ballot
29 Apr 2026BoardAudited Results & Final Dividend
22 Jan 2026BoardQuarterly Results
5 Nov 2025BoardQuarterly Results
23 Jul 2025MeetingAnnual General Meeting

Show 12 older events

23 Jul 2025BoardQuarterly Results
30 Jun 2025MeetingPostal Ballot
27 Jun 2025Dividend₹1.25 per share · 13% · Final dividend
23 Apr 2025BoardAudited Results & Final Dividend
23 Jan 2025BoardQuarterly Results
23 Oct 2024BoardQuarterly Results
24 Jul 2024MeetingAnnual General Meeting
28 Jun 2024Dividend₹1.25 per share · 13% · Final dividend
26 Jul 2023MeetingAnnual General Meeting
30 Jun 2023Dividend₹0.50 per share · 5% · Final dividend
30 Jun 2022Dividend₹0.50 per share · 5% · Final dividend
30 Jun 2022Dividend₹0.50 per share · 5% · Special special dividend

About Syngene International

Biotechnology & Drugs

Syngene International Limited is an India-based integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. The Company's services include discovery, development, manufacturing, SynVent Integrated Drug discovery, dedicated centers, and Center for Advanced Protein Studies (CAPS). Its discovery services span the entire spectrum of early-stage research from target identification to delivery of drug candidates for further development. It offers preclinical development, active pharmaceutical ingredient and drug product development for both small molecules and biologics. It has capabilities for current Good Manufacturing Practices (cGMP) manufacturing from benchtop volume to commercial scale. SynVent is its drug discovery platform for enabling fully integrated therapeutic drug discovery and development across small molecules, new modalities and biologics.

Key people

Kiran Mazumdar ShawExecutive Chairman of the Board
Siddharth MittalChief Executive Officer, Managing Director, Additional Director
Deepak JainChief Financial Officer
Maninder Kapoor PuriChief Human Resources Officer
Alex Del PrioreSenior Vice President - Manufacturing Services
Gaurav KushwahaChief Technology Officer

Company facts

NSE symbolSYNGENE
BSE code539268
ISININE398R01022
IndustryBiotechnology & Drugs
IndexNIFTY 500
Market cap₹15,385 Cr
Revenue (FY26)₹3,739 Cr
Net profit (FY26)₹317 Cr

In the News

Recent headlines about Syngene International — they open on Mint in a new tab.

Biocon eyes crown of world’s top insulin supplier amid rush for GLP-1
Biocon, currently the third-largest insulin supplier by volume, has invested “big time” in ramping up production capacity, Chairperson Kiran Mazumdar-Shaw says.
16 Jun 2026 · 2 min read · Mint ↗
What Nippon India Small Cap Fund bought and sold in May 2026 — top 10 holdings revealed
Nippon India Small Cap Fund is the largest open-ended small-cap mutual fund in India with an AUM of ₹72,673 crores. Here's a closer look at the fund's portfolio activity in May 2026, highlighting the stocks it added and trimmed during the month, along with its top 10 holdings.
10 Jun 2026 · 4 min read · Mint ↗
Stock market today: Gift Nifty hints muted opening; US-Iran war, gold to crude oil prices — eight stocks to buy or sell
Indian stock markets are expected to open flat-to-negative on June 9, 2026, with Gift Nifty at 23,121.5. This follows a significant drop on Monday due to geopolitical tensions and rising crude prices, amid cautious global sentiment and increasing market volatility.
9 Jun 2026 · 5 min read · Mint ↗
Top Gainers & Losers on May 5: Wockhardt, Tata Tech, Gabriel India, Dabur, Adani Green Energy among top gainers
Indian markets showed volatility on May 5 amid escalating US-Iran tensions. The Nifty 50 ended up 0.36%, while the Sensex declined 0.33%. Notable gainers included CreditAccess Grameen and Wockhardt, though profit-taking led to losses in several other stocks.
5 May 2026 · 2 min read · Mint ↗
Top Gainers and Losers on April 30: Vedanta, Waaree Energies, Eternal, Adani Energy, Ceat, among top losers
The Indian stock market declined in April's final session due to rising crude oil prices and a weak rupee, with the Nifty 50 down 0.73% and the Sensex 0.78%. Both indices recorded over 7% gains for the month, while the rupee hit a record low against the dollar.
30 Apr 2026 · 3 min read · Mint ↗
Buy or sell: Vaishali Parekh recommends two intraday stocks to buy today — 16 March 2026
Buy or sell stocks for 16 March: Vaishali Parekh recommends two intraday stocks to buy today — Syngene International, Tata Consumer Products
16 Mar 2026 · 2 min read · Mint ↗
Buy or sell: Sumeet Bagadia recommends three stocks to buy on Monday — 16 March 2026
Buy or sell: Sumeet Bagadia recommends three stocks to buy on Monday — Syngene International, Muthoot Finance, and Tata Consumer Products
14 Mar 2026 · 2 min read · Mint ↗
Buy or sell: Vaishali Parekh recommends three intraday stocks to buy today — 19 February 2026
Buy or sell: Vaishali Parekh recommends three intraday stocks to buy today — Syngene International, Carborundum Universal, and Hyundai Motor India
19 Feb 2026 · 2 min read · Mint ↗

Stock data comes from the exchange feed via our data provider and may be delayed. It is for information only and is not a recommendation to buy or sell. See all stocks →

Frequently Asked Questions

Syngene International (NSE: SYNGENE) last traded at ₹380.00 on the NSE, down 0.34% (₹1.30) on the day, as of 24 Sep 2026, 9:57 AM. On the BSE it was ₹380.30. The day's range was ₹379.00 – ₹384.20.

Syngene International's 52-week high is ₹678.00 (7 Jan 2026) and its 52-week low is ₹360.35 (21 Sep 2026). At ₹380.00 the share is 44.0% below its high and 5.5% above its low.

Syngene International's market capitalisation is ₹15,385 Cr (₹15,385 Cr). It is part of the NIFTY 500 index.

Syngene International's P/E ratio (trailing 12 months) is 79.96. The sector average is 46.34, so investors pay 73% more for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹5.49.

Syngene International shares are down 40.67% over the last year, down 41.34% so far this year, down 8.81% over 6 months, down 13.79% over 3 months. Over the last year the stock did 34.91% worse than the market.

In FY26 (year to Mar 2026), Syngene International reported revenue of ₹3,739 Cr (up 2.64% on the year before) and a net profit of ₹317 Cr. Earnings per share were ₹7.87.

Yes. Syngene International's latest dividend is ₹1.25 per share (13%, final dividend), with an ex-date of 25 Jun 2026. The dividend yield is 0.33%. It has paid 6 dividends in the records shown on this page.

Of 8 analysts covering Syngene International, 5 are bullish (2 strong buy, 3 buy), 2 say hold and 1 are bearish. The consensus is Buy (average rating 2.38 on a scale where 1 is Strong Buy and 5 is Strong Sell). Analyst views are opinions, not a guarantee.

As of Jun 2026: Promoter 52.59%, FII 11.82%, MF 25.78%, Other 9.81%. Promoter holding fell by 0.09 percentage points from Mar 2026.

Syngene International's listed peers in Biotechnology & Drugs include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, Zydus Lifesciences. By market capitalisation it ranks #6 of 6 in this group.

Price returns

Moving averages — price is above 1 of 6

Year by year

Quarter by quarter

Balance sheet — FY26

Cash flow — FY26

Votes

How the votes changed

Valuation Is the price reasonable?

Profitability Of every ₹100 of sales, how much is kept?

Returns & efficiency How well does it use its money?

Growth Is the business getting bigger?

Financial strength Can it pay its bills and debts?

Per share What each share stands for

Valuation

Per share

Margins

Growth

Financial strength

Returns & efficiency

Price & volume

Corporate calendar

Key people

Company facts

Frequently Asked Questions

What is Syngene International share price today?

What is the 52-week high and low of Syngene International shares?

What is the market capitalisation of Syngene International?

What is the P/E ratio of Syngene International?

How has Syngene International stock performed?

What were Syngene International's latest annual results?

Does Syngene International pay a dividend?

What do analysts recommend for Syngene International shares?

What is the shareholding pattern of Syngene International?

Who are Syngene International's competitors?